Investor relations

RNS announcements

Financial reports

Shareholder circulars

Share price information

Share capital information

Advisors

Analyst Coverage

Corporate presentation

RNS announcements

Financial reports

Shareholder circulars

Share price information

Share capital information

Advisors

Analyst Coverage

Corporate presentation

RNS announcements

Financial reports

Shareholder circulars

Share price information

Share capital information

Advisors

Analyst Coverage

Corporate presentation

RNS announcements

Financial reports

Shareholder circulars

Share price information

Share capital information

Advisors

Analyst Coverage

Corporate presentation

RNS announcements

Financial reports

Shareholder circulars

Share price information

Share capital information

Advisors

Analyst Coverage

Corporate presentation

Share price information

Main Market

The number of shares in issue is 5,908,770,690 ordinary shares of £0.001 each (including shares held as treasury shares). No ordinary shares are held as treasury shares and therefore the total number of voting rights in the Company is 5,908,770,690. There are no restrictions on the transfer of securities in the Company. The Company’s securities have not been admitted to trading on any other exchanges

Therapeutic focus

Therapeutic focus

R&D

R&D

Investor relations

Investor relations

About

About

News

News

Contact

Contact

Media pack

Media pack

Solvonis Therapeutics

©

2025

Solvonis Therapeutics

Privacy Policy

Site by: Cohesion Labs

Therapeutic focus

Therapeutic focus

R&D

R&D

Investor relations

Investor relations

About

About

News

News

Contact

Contact

Media pack

Media pack

Solvonis Therapeutics

©

2025

Solvonis Therapeutics

Privacy Policy

Site by: Cohesion Labs

Therapeutic focus

Therapeutic focus

R&D

R&D

Investor relations

Investor relations

About

About

News

News

Contact

Contact

Media pack

Media pack

Solvonis Therapeutics

©

2025

Solvonis Therapeutics

Privacy Policy

Site by: Cohesion Labs

Therapeutic focus

Therapeutic focus

R&D

R&D

Investor relations

Investor relations

About

About

News

News

Contact

Contact

Media pack

Media pack

Solvonis Therapeutics

©

2025

Solvonis Therapeutics

Privacy Policy

Site by: Cohesion Labs

Therapeutic focus

Therapeutic focus

R&D

R&D

Investor relations

Investor relations

About

About

News

News

Contact

Contact

Media pack

Media pack

Solvonis Therapeutics

©

2025

Solvonis Therapeutics

Privacy Policy

Site by: Cohesion Labs

Solvonis Therapeutics

Therapeutic focus

Therapeutic focus

R&D

R&D

Investor relations

Investor relations

About

About

News

News

Contact

Contact

Solvonis Therapeutics

Therapeutic focus

Therapeutic focus

R&D

R&D

Investor relations

Investor relations

About

About

News

News

Contact

Contact

Solvonis Therapeutics

Menu

Solvonis Therapeutics

Menu

Solvonis Therapeutics

Therapeutic focus

Therapeutic focus

R&D

R&D

Investor relations

Investor relations

About

About

News

News

Contact

Contact